Eosinophilic annular erythema treated with dupilumab | Zendy

Gordon Samantha C. | Zendy; Robinson Sarah N. | Zendy; Abudu Minawaer | Zendy; Her Michelle | Zendy; Deverapalli Sandyha | Zendy; Levin Adrianne | Zendy; Schmidt Birgitta A. R. | Zendy; Gellis Stephen E. | Zendy; Rosmarin David | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Eosinophilic annular erythema treated with dupilumab

Author(s) -

Gordon Samantha C.,

Robinson Sarah N.,

Abudu Minawaer,

Her Michelle,

Deverapalli Sandyha,

Levin Adrianne,

Schmidt Birgitta A. R.,

Gellis Stephen E.,

Rosmarin David

Publication year - 2018

Publication title -

pediatric dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.542

H-Index - 73

eISSN - 1525-1470

pISSN - 0736-8046

DOI - 10.1111/pde.13533

Subject(s) - dupilumab , medicine , erythema , eosinophilia , eosinophilic , dermatology , eosinophil , pathology , immunology , atopic dermatitis , asthma

Eosinophilic annular erythema is a rare, benign, recurrent condition characterized by annular skin lesions, tissue eosinophilia, and resistance to a variety of treatments. There are fewer than 30 cases reported in the English literature, 7 of which are in children. We present a case of recurrent eosinophilic annular erythema in an adolescent that was successfully treated with dupilumab, an interleukin‐4 receptor alpha antagonist.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research